Study of Viral Load Decay Rates in HIV Infected Participants Starting Treatment With Raltegravir (RAL) and Emtricitabine/Tenofovir Disoproxil Fumarate (TDF)

Exclusion Criteria

• •Received HIV-specific immunizations within 6 months prior to study entry
• •Received immunizations within 6 months prior to study entry
• •Known allergy or sensitivity to study drugs
• •Any participant with an acute AIDS-defining opportunistic infection (OI) who is not clinically stable or who has not been on therapy for the OI for at least 30 days prior to study entry
• •Treatment with immune modulators or any investigational therapy within 30 days prior to study entry
• •Evidence of HIV seroconversion within 6 months prior to study entry
• •Illness requiring systemic treatment and/or hospitalization
• •Substance abuse that, in the opinion of the investigator, would interfere with adherence to study requirements
• •Requirement for any current medications that are prohibited with any study medication. More information on this criterion can be found in the protocol.
• •Evidence of any major resistance-associated mutation on any genotype performed prior to study entry or at the time of screening. More information on this criterion can be found in the protocol.
• •Abnormal laboratory values. More information on this criterion can be found in the protocol.
• •Pregnant or breastfeeding